SCHEMBL256775

SCHEMBL256775

COCc1cc(C(=O)N(C)OC)ccc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.41
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 1/20 0.37
ALDH1A1 P00352 3/20 0.35
HSP90AA1 P07900 2/20 0.35
HSP90AB1 P08238 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAPT P10636 2/20 0.33
CLK1 P49759 1/20 0.33
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
GAA P10253 1/20 0.33
SLC6A3 Q01959 1/20 0.33
POLB P06746 1/20 0.33
CYP1A2 P05177 1/20 0.33
BLM P54132 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
SLC6A2 P23975 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361324 0.88 MLYCD (0.43) MLYCDMEN1KMT2AHTTHPGD
SCHEMBL30602390 0.88 ALDH1A1 (0.42) MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL17894222 0.87 MLYCD (0.42) MLYCDMEN1KMT2AHTTHPGD
SCHEMBL25257215 0.84 MLYCD (0.36) MLYCDMEN1KMT2AHTTHPGD
SCHEMBL26566639 0.83 MLYCD (0.36) MLYCDMEN1KMT2AHTTHPGD
SCHEMBL25256351 0.82 MLYCD (0.38) MLYCDMEN1KMT2AHTTHPGD
SCHEMBL29133079 0.80 PRKCE (0.36) MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL30622253 0.80 ALDH1A1 (0.48) MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL24595665 0.80 ALDH1A1 (0.48) MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL408849 0.80 CA1 (0.44) HTTALDH1A1TDP1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 MLYCD 3030/4885MEN1 325/4885KMT2A 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.